<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Clin Psychopharmacol Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Psychopharmacol Neurosci</journal-id>
<journal-title-group>
<journal-title>Clinical Psychopharmacology and Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1738-1088</issn>
<issn pub-type="epub">2093-4327</issn>
<publisher>
<publisher-name>Korean College of Neuropsychopharmacology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28783931</article-id>
<article-id pub-id-type="pmc">5565080</article-id>
<article-id pub-id-type="doi">10.9758/cpn.2017.15.3.229</article-id>
<article-id pub-id-type="publisher-id">cpn-15-229</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Low Retinal Dehydrogenase 1 (RALDH1) Level in Prepubertal Boys with Autism Spectrum Disorder: A Possible Link to Dopamine Dysfunction?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pavăl</surname>
<given-names>Denis</given-names>
</name>
<xref ref-type="aff" rid="af1-cpn-15-229">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rad</surname>
<given-names>Florina</given-names>
</name>
<xref ref-type="aff" rid="af2-cpn-15-229">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rusu</surname>
<given-names>Răzvan</given-names>
</name>
<xref ref-type="aff" rid="af1-cpn-15-229">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niculae</surname>
<given-names>Alexandru-Ştefan</given-names>
</name>
<xref ref-type="aff" rid="af1-cpn-15-229">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Colosi</surname>
<given-names>Horaţiu Alexandru</given-names>
</name>
<xref ref-type="aff" rid="af3-cpn-15-229">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dobrescu</surname>
<given-names>Iuliana</given-names>
</name>
<xref ref-type="aff" rid="af2-cpn-15-229">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dronca</surname>
<given-names>Eleonora</given-names>
</name>
<xref ref-type="aff" rid="af1-cpn-15-229">1</xref>
<xref ref-type="corresp" rid="c1-cpn-15-229"></xref>
</contrib>
</contrib-group>
<aff id="af1-cpn-15-229">
<label>1</label>Department of Molecular Sciences, Faculty of Medicine, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, 
<country>Romania</country></aff>
<aff id="af2-cpn-15-229">
<label>2</label>Alexandru Obregia Psychiatry Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, 
<country>Romania</country></aff>
<aff id="af3-cpn-15-229">
<label>3</label>Department of Medical Informatics and Biostatistics, Faculty of Medicine, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, 
<country>Romania</country></aff>
<author-notes>
<corresp id="c1-cpn-15-229">Address for correspondence: Eleonora Dronca, MD, PhD, Department of Molecular Sciences, Faculty of Medicine, Iuliu Haţieganu University of Medicine and Pharmacy, Str. Victor Babeş Nr. 8, 400012 Cluj-Napoca, Romania, Tel: +40-740198218, Fax: +40-264597257, E-mail: <email>eleonora.dronca@umfcluj.ro</email>.</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>8</month>
<year>2017</year>
</pub-date>
<volume>15</volume>
<issue>3</issue>
<fpage>229</fpage>
<lpage>236</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>8</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>9</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017, Korean College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>Retinal dehydrogenase 1 (RALDH1) is a cytosolic enzyme which acts both as a source of retinoic acid (RA) and as a detoxification enzyme. RALDH1 has key functions in the midbrain dopaminergic system, which influences motivation, cognition, and social behavior. Since dopamine has been increasingly linked to autism spectrum disorder (ASD), we asked whether RALDH1 could contribute to the autistic phenotype. Therefore, we investigated for the first time the levels of RALDH1 in autistic patients. To further assess the detoxification function of RALDH1, we also explored 4-hydroxynonenal protein adducts (4-HNE PAs) and reduced glutathione (GSH) levels. Moreover, considering the effect of testosterone on RALDH1 expression, we measured the second to fourth digit ratio (2D:4D ratio) for both hands, which reflects exposure to prenatal testosterone.</p>
</sec>
<sec>
<title>Methods</title>
<p>Male patients with ASD (n=18; age, 62.9±4.3 months) and healthy controls (n=13; age, 78.1±4.9 months) were examined. Erythrocyte RALDH1, serum 4-HNE PAs and erythrocyte GSH levels were measured using colorimetric assays, and digit lengths were measured using digital calipers.</p>
</sec>
<sec>
<title>Results</title>
<p>We found significantly lower (−42.9%) RALDH1 levels in autistic patients as compared to controls (p=0.032). However, there was no difference in 4-HNE PAs levels (p=0.368), GSH levels (p=0.586), or 2D:4D ratios (p=0.246 in the left hand, p=0.584 in the right hand) between healthy controls and autistic subjects.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>We concluded that a subset of autistic patients had a low RALDH1 level. These results suggest that low RALDH1 levels could contribute to the autistic phenotype by reflecting a dopaminergic dysfunction.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Autistic disorder</kwd>
<kwd>Retinal dehydrogenase</kwd>
<kwd>Dopamine</kwd>
<kwd>4-Hydroxy-2-nonenal</kwd>
<kwd>Glutathione</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disorders characterized by persistent deficits in social communication and social interaction and restricted patterns of behavior, interests and activities.<xref ref-type="bibr" rid="b1-cpn-15-229">1)</xref> Interest in ASD has increased over time as prevalence has risen progressively over the last decades, some modern estimates putting it as high as 1 in 88 children.<xref ref-type="bibr" rid="b2-cpn-15-229">2)</xref> Intriguingly, ASD are strongly biased towards males, with a male to female ratio of 4:1.<xref ref-type="bibr" rid="b3-cpn-15-229">3)</xref> Although several theories regarding the pathogenesis of ASD have emerged, their etiology remains largely unknown.<xref ref-type="bibr" rid="b4-cpn-15-229">4)</xref> Evidence suggests that ASD is not a single disorder, but rather a set of different variants, each with its own characteristics and etiologies.<xref ref-type="bibr" rid="b5-cpn-15-229">5)</xref></p>
<p>The diffuse modulatory systems of the brain represent groups of neurons which form widely dispersed connections throughout the brain, modulating vast assemblies of postsynaptic neurons. The ventral tegmental area (VTA) of the midbrain is the origin of one such diffuse modulatory system.<xref ref-type="bibr" rid="b6-cpn-15-229">6)</xref> The dopaminergic fibers arising from the VTA project to the prefrontal cortex (PFC) and to regions of the limbic system, such as the nucleus accumbens (NAcc), forming the mesocorticolimbic (MCL) circuit.<xref ref-type="bibr" rid="b7-cpn-15-229">7)</xref> This circuit is involved in high order brain functions, such as reward, emotional social behavior, motivation and cognition.<xref ref-type="bibr" rid="b6-cpn-15-229">6</xref>,<xref ref-type="bibr" rid="b8-cpn-15-229">8)</xref> The midbrain dopaminergic system is thought to be involved in neuropsychiatric disorders.<xref ref-type="bibr" rid="b9-cpn-15-229">9)</xref> Although scarce, evidence suggests dopaminergic dysfunction in autistic subjects.<xref ref-type="bibr" rid="b10-cpn-15-229">10</xref>–<xref ref-type="bibr" rid="b12-cpn-15-229">12)</xref></p>
<p>The midbrain dopaminergic system relies on the function of retinal dehydrogenase 1 (RALDH1). RALDH1 is a ubiquitously distributed cytosolic enzyme which plays key roles in the dopaminergic neurons both as a source of retinoic acid (RA) and as a detoxification enzyme.<xref ref-type="bibr" rid="b13-cpn-15-229">13</xref>,<xref ref-type="bibr" rid="b14-cpn-15-229">14)</xref> RALDH1 catalyzes the oxidation of retinal to RA, which is essential for the differentiation, development and survival of dopaminergic neurons, both in the developing and in the adult brain.<xref ref-type="bibr" rid="b15-cpn-15-229">15</xref>,<xref ref-type="bibr" rid="b16-cpn-15-229">16)</xref> Moreover, RALDH1 plays a role in the cellular defense against oxidative stress, through oxidation of the aldehydes derived from lipid peroxidation (LPO), such as 4-hydroxynonenal (4-HNE).<xref ref-type="bibr" rid="b17-cpn-15-229">17)</xref> In the dopaminergic neurons, RALDH1 catalyzes the oxidation of 3, 4-dihydroxyphenylacetaldehyde (DOPAL), a metabolite of dopamine which renders such neurons susceptible to oxidative stress.<xref ref-type="bibr" rid="b18-cpn-15-229">18)</xref> RALDH1 is also involved in the degradation of dopamine itself.<xref ref-type="bibr" rid="b19-cpn-15-229">19)</xref> Although low levels of RALDH1 have been reported in neuropsychiatric conditions with hypothesized dopaminergic involvement, this aspect has not been studied in autistic subjects so far.<xref ref-type="bibr" rid="b13-cpn-15-229">13</xref>,<xref ref-type="bibr" rid="b20-cpn-15-229">20)</xref></p>
<p>Considered a reliable marker of oxidative stress, 4-HNE is a reactive aldehyde derived from LPO which yields general cytotoxicity, thought to be involved in various pathological conditions.<xref ref-type="bibr" rid="b21-cpn-15-229">21)</xref> Due to its reactivity, 4-HNE readily forms stable adducts with various proteins (4-HNE protein adducts, 4-HNE PAs), and consequently affects those biological function.<xref ref-type="bibr" rid="b22-cpn-15-229">22</xref>,<xref ref-type="bibr" rid="b23-cpn-15-229">23)</xref> 4-HNE has direct dopaminergic neurotoxicity and dopaminergic functional effects, such as modulation of dopamine receptors and of dopamine uptake through the dopamine transporter protein.<xref ref-type="bibr" rid="b24-cpn-15-229">24</xref>–<xref ref-type="bibr" rid="b27-cpn-15-229">27)</xref> Thus far, one study reported increased 4-HNE PAs levels in autistic children as compared to controls.<xref ref-type="bibr" rid="b21-cpn-15-229">21)</xref></p>
<p>Even though RALDH1 plays an important role in the metabolism of 4-HNE, the main enzyme involved in the 4-HNE detoxification outside the brain is glutathione-S-transferase (GST).<xref ref-type="bibr" rid="b17-cpn-15-229">17</xref>,<xref ref-type="bibr" rid="b21-cpn-15-229">21)</xref> GST conjugates the reduced glutathione (GSH) with toxic compounds, such as 4-HNE, in order to eliminate them.<xref ref-type="bibr" rid="b28-cpn-15-229">28)</xref> GSH is the main low molecular weight antioxidant synthesized in cells, its level reflecting the oxidative stress status.<xref ref-type="bibr" rid="b29-cpn-15-229">29)</xref> Although not consistently, studies show that autistic subjects exhibit low GSH levels.<xref ref-type="bibr" rid="b30-cpn-15-229">30)</xref></p>
<p><italic>RALDH1</italic> gene expression has been reported to be directly regulated by androgens and estrogens.<xref ref-type="bibr" rid="b31-cpn-15-229">31</xref>,<xref ref-type="bibr" rid="b32-cpn-15-229">32)</xref> More important, molecular pathways describing a “transfer of signaling” from sex hormones to RA through the action of RALDH1 were revealed.<xref ref-type="bibr" rid="b33-cpn-15-229">33</xref>,<xref ref-type="bibr" rid="b34-cpn-15-229">34)</xref> Given the strong male bias, it has been suggested that ASD may arise as a result of prenatal exposure to elevated levels of testosterone, especially between weeks 8 and 24 of gestational age.<xref ref-type="bibr" rid="b35-cpn-15-229">35)</xref> Considering that the direct measurement of prenatal testosterone level is technically difficult, the ratio between the length of the second and fourth digit (2D:4D ratio) was used as a proxy, given that it is negatively correlated to prenatal testosterone.<xref ref-type="bibr" rid="b36-cpn-15-229">36)</xref></p>
<p>This work aimed to investigate the erythrocyte RALDH1 level in autistic patients as a peripheral indicator of the RALDH1 level in dopaminergic neurons. This could provide information regarding the RA synthesis in the autistic midbrain dopaminergic system. Moreover, to obtain information about the detoxification function of RALDH1 as well, we evaluated the 4-HNE PAs serum levels. Given the fact that GSH is also involved in the 4-HNE detoxification, we further evaluated the GSH levels in order to minimize the confounding factors linked to the metabolism of 4-HNE. Lastly, the 2D:4D ratio was used in order to assess any potential influences linked to fetal testosterone levels.</p>
</sec>
<sec sec-type="methods">
<title>METHODS</title>
<sec>
<title>Study Population</title>
<p>In this case-control study, we studied samples from the male population aged 48 to 96 months (i.e., 4 to 8 years) old. Subjects diagnosed with any genetic, metabolic, or neurologic condition, as well as those having a history of acute or chronic inflammatory disease or taking long-term medication were excluded from the study.</p>
<p>Male patients with ASD (n=18), as well as sex-matched healthy controls (n=13) participated in the study. The autistic subjects were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for ASD.<xref ref-type="bibr" rid="b1-cpn-15-229">1)</xref> Moreover, their behavior was individually evaluated through specific diagnostic tools, using the Childhood Autism Rating Scale and Autism Diagnostic Observation Schedule.<xref ref-type="bibr" rid="b37-cpn-15-229">37</xref>,<xref ref-type="bibr" rid="b38-cpn-15-229">38)</xref> Also, the parents of each autistic subject completed a questionnaire regarding the developmental history of the child.</p>
<p>The healthy controls were selected during routine health checks. Parents of healthy individuals that requested routine check-ups were asked to participate in the study on a voluntary basis. During their routine visit to the Pediatrics Department of the Iuliu Haţieganu University of Medicine and Pharmacy, the children underwent digit length measurements in addition to the standard clinical examination. Blood samples were obtained from participants that opted to have samples drawn as part of their check-ups. The full set of biological samples and appropriate digit lentgh measurements were eventually obtained from a total of 13 healthy males.</p>
<p>We chose to include only males in this study because ASD is more prevalent among males. Given the assumptions (as detailed in the Discussion section) about hormonal influences on RALDH1 levels (and therefore, the possibility of these differences acting on ASD pathogenesis), choosing to include only males would limit confounding factors related to sex and internal hormonal environment. The age group was further carefully selected so as to reduce confounding levels of hormonal activity to a minimum (as detailed in the Discussion section).</p>
<p>Ethical committee approval from the Iuliu Haţieganu University of Medicine and Pharmacy and informed consent from parents of all participating subjects’ were obtained.</p>
</sec>
<sec>
<title>Sample Collection and Preparation</title>
<p>Venous blood samples were obtained from each subject and collected into 5 ml vacutainers containing clot activator or K2EDTA, in order to obtain serum and erythrocytes, respectively. The samples were processed as soon as possible in order to avoid alterations.</p>
<sec>
<title>Serum</title>
<p>The vacutainers containing clot activator were centrifuged for 5 minutes at 3,500 rpm, and then the serum was collected, aliquoted and stored at −80°C until analysis.</p>
</sec>
<sec>
<title>Washed erythrocytes</title>
<p>After mixing the whole blood by gentle inversion of the vacutainer, an amount of 1 ml of whole blood was aspirated and centrifuged for 3 minutes at 3,500 rpm, and then the plasma and the buffy coat on the erythrocyte sediment were removed. Then the erythrocytes were washed three times with 1 ml of 0.9% NaCl solution and centrifuged for 3 minutes at 3,500 rpm after each wash. Next, the erythrocytes were resuspended in cold 0.9% NaCl solution in order to obtain the initial volume (1 ml) and the mixture was aliquoted and stored at −80°C.</p>
</sec>
<sec>
<title>Erythrocyte lysate</title>
<p>Prior to the analysis, the frozen suspensions of erythrocytes (in 0.9% NaCl solution) were thawed and subjected to another freeze-thaw cycle in order to break up the cell membranes. Then the erythrocyte lysates were centrifuged for 5 minutes at 5,000 <italic>g</italic>, 2°C to 8°C. The supernatant was collected and assayed immediately.</p>
</sec>
</sec>
<sec>
<title>Instruments, Biochemical Tests, and Calculation of Results</title>
<p>For the colorimetric enzyme-linked immunosorbent assays (ELISA) a microplate reader (Tecan Sunrise<sup>TM</sup>; Tecan, Männedorf, Switzerland) was used. For the quantitative colorimetric assays, a double beam ultraviolet-visible spectrophotometer (JASCO V-530; JASCO Inc., Easton, MD, USA) was used. In order to calculate the sample concentrations, standard curves were constructed using Curve Expert 1.4 (Daniel Hyams, Madison, AL, USA), software capable of generating a four-parameter logistic curve fit.</p>
<sec>
<title>RALDH1 concentration</title>
<p>RALDH1 level in the erythrocyte lysates was determined with a quantitative sandwich enzyme immunoassay technique using the sandwich ELISA kit from Cusabio Biotech Co., Ltd. (CSB-EL001565HU; Hubei, China) according to the manufacturer’s instructions.</p>
</sec>
<sec>
<title>4HNE-PAs concentration</title>
<p>4HNE-PAs level in the serum was determined using competitive ELISA kit from Cell Biolabs, Inc. (STA-838; San Diego, CA, USA), according to the manufacturer’s instructions.</p>
</sec>
<sec>
<title>GSH concentration</title>
<p>GSH level in the erythrocyte lysates was estimated according to the method described by Akerboom and Sies.<xref ref-type="bibr" rid="b39-cpn-15-229">39)</xref></p>
</sec>
</sec>
<sec>
<title>The 2D:4D Ratio</title>
<p>To determine 2D:4D ratio, digital calipers were used to measure digit length either directly on the subjects’ hands or from photocopies of the palmar surface of the hand. The lengths of the second and fourth digits from each hand were measured from the proximal crease at the base of the finger to the tip of the finger, using a standard method.<xref ref-type="bibr" rid="b40-cpn-15-229">40)</xref></p>
</sec>
<sec>
<title>Statistical Analysis</title>
<p>Data were analyzed using the IBM SPSS Statistics (version 20.0.0; IBM Co., Armonk, NY, USA), and two-tailed <italic>p</italic> values of less than 0.05 were considered significant. All variables were tested for normal distribution using the Shapiro-Wilk test. Normally distributed data were presented as mean±standard deviation. For asymmetric data, the median was chosen as a measure of central tendency. To assess homogeneity of variance for a given variable, Levene’s test was used. Data between groups were compared using the independent-samples <italic>t</italic> test (for normally distributed data) or the Mann-Whitney <italic>U</italic> test (for asymmetric data). Correlations between groups were assessed using Pearson’s correlations (for normally distributed data) or Spearman’s rank correlations (for asymmetric data). Linear regression was used in order to assess the relationship between RALDH1 and the participants’ age.</p>
<p>No multiple comparisons adjustment was used in our study since we made a small number of planned comparisons with clearly defined hypotheses pertaining to different biochemical pathways or anthropometric measurements. As such there is no universally available null hypothesis that encompasses all our parameters into one single purported theory and there has no retro-fitting of various hypotheses after the collection of data.</p>
</sec>
</sec>
<sec sec-type="results">
<title>RESULTS</title>
<sec>
<title>Age</title>
<p>Between the autistic patients (age, 62.9±4.3 months; range, 38–102 months) and the control subjects (age, 78.1±4.9 months; range, 49–106 months) there was a significant age difference (<italic>p</italic>=0.028).</p>
</sec>
<sec>
<title>RALDH1 Level</title>
<p>We found significantly lower (−42.9%) erythrocyte RALDH1 level in autistic children compared to the healthy controls (<italic>p</italic>=0.032) (<xref ref-type="fig" rid="f1-cpn-15-229">Fig. 1</xref>).</p>
</sec>
<sec>
<title>4HNE-PAs Level</title>
<p>We found no significant difference in serum 4HNE-PAs level between the ASD group and the control group (<italic>p</italic>=0.368). There was a higher (+30.5%) serum 4HNE-PAs level in the control group (<xref ref-type="fig" rid="f2-cpn-15-229">Fig. 2</xref>).</p>
</sec>
<sec>
<title>GSH Level</title>
<p>We found no significant difference in erythrocyte GSH level between the ASD group and the control group (<italic>p</italic>=0.586) (<xref ref-type="fig" rid="f3-cpn-15-229">Fig. 3</xref>).</p>
</sec>
<sec>
<title>The 2D:4D Ratios</title>
<p>We found no significant difference in 2D:4D ratio in the left hand (<italic>p</italic>=0.246) or the right hand (<italic>p</italic>=0.584) between ASD group and the control group (<xref ref-type="fig" rid="f4-cpn-15-229">Fig. 4</xref>).</p>
</sec>
<sec>
<title>RALDH1 and 4HNE-PAs Correlation</title>
<p>We found a weak, non-statistically significant correlation between RALDH1 and 4HNE-PAs levels (r<sub>s</sub>=0.182, <italic>p</italic>=0.326).</p>
</sec>
<sec>
<title>RALDH1 and 2D:4D Ratios Correlations</title>
<p>We found a weak, non-statistically significant correlation between RALDH1 levels and left hand 2D:4D ratio (r=0.284, <italic>p</italic>=0.179). Also, there was no correlation between RALDH1 levels and right hand 2D:4D ratio (r=−0.05, <italic>p</italic>=0.791).</p>
</sec>
</sec>
<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>Our study found significantly lower RALDH1 levels, but no difference in 4-HNE PAs level, GSH level, or 2D:4D ratios in the ASD group compared to the control group.</p>
<p>In dopaminergic neurons, RALDH1 plays key roles both as a source of RA and as a detoxification enzyme.<xref ref-type="bibr" rid="b13-cpn-15-229">13</xref>,<xref ref-type="bibr" rid="b18-cpn-15-229">18)</xref> RALDH1 is highly and specifically expressed in the VTA dopaminergic neurons, suggesting RALDH1’s strong involvement in controlling the dopaminergic function and signaling in the MCL circuit.<xref ref-type="bibr" rid="b13-cpn-15-229">13)</xref> The observed decrease in the RALDH1 level could reflect an insufficient synthesis of RA in the VTA. A lower RA level would deprive the MCL circuit of a critical factor for the circuits’ development and function and would ultimately lead to alterations in motivation, emotional behavior and cognition.<xref ref-type="bibr" rid="b6-cpn-15-229">6</xref>,<xref ref-type="bibr" rid="b8-cpn-15-229">8)</xref> Furthermore, considering the detoxification function of RALDH1, a low RALDH1 level would render VTA neurons more susceptible to reactive aldehydes, such as the neurotoxic DOPAL and 4-HNE. The aldehyde toxicity stemming from these compounds could also lead to the circuit’s malfunction. Curiously, studies of autistic subjects reveal anomalies directly linked to MCL circuit dysfunction, such as reduced release of dopamine in prefrontal regions, decreased NAcc activation and hypoactivation of the reward circuit.<xref ref-type="bibr" rid="b10-cpn-15-229">10</xref>–<xref ref-type="bibr" rid="b12-cpn-15-229">12)</xref> However, the RALDH1 role in the dopaminergic molecular machinery supporting these high order brain functions remains to be determined.</p>
<p>Intriguingly, RALDH1 is involved in the degradation of dopamine.<xref ref-type="bibr" rid="b19-cpn-15-229">19)</xref> Thus, a low RALDH1 level could expose the MCL circuit to higher levels of dopamine. In fact, ASD were hypothesized to be associated with dopaminergic hyperactivity of the MCL circuit, given that dopaminergic antagonists like risperidone and aripiprazole are the only drugs approved for the control of ASD-associated behavior.<xref ref-type="bibr" rid="b41-cpn-15-229">41</xref>,<xref ref-type="bibr" rid="b42-cpn-15-229">42)</xref> However, ASD were also hypothesized to be associated with dopaminergic hypoactivity.<xref ref-type="bibr" rid="b43-cpn-15-229">43)</xref> Thus, a decrease in the RALDH1 level could be the result of a compensatory down-regulation in order to limit the dopamine degradation and prolong its half-life. Future investigations are certainly needed in order to establish the characteristics of dopaminergic signaling in ASD. Lately, authors increasingly involved dopamine in ASD, widening the perspective of finding new drugs for the control of ASD-associated behavior.<xref ref-type="bibr" rid="b44-cpn-15-229">44)</xref></p>
<p>Given the reports of oxidative stress in ASD and the low observed RALDH1 level, we expected to see significantly higher levels of 4-HNE PAs in the ASD group compared to the control group.<xref ref-type="bibr" rid="b45-cpn-15-229">45)</xref> However, the ASD group had lower (−30.5%) levels of 4-HNE PAs, although not significantly different. Also, our data showed that there was no significant correlation between the RALDH1 level and 4-HNE PAs level. The lower 4-HNE PAs levels in autistic subjects could mean that several RALDH1-independent mechanisms account for the 4-HNE metabolism, such as detoxification by GSH. In this respect, we evaluated the GSH levels, but we did not find a significant difference between the two groups. However, the GSH values of the control group were spread on a larger interval compared to those of the ASD group. Further studies are necessary in order to establish if the 4-HNE PAs are a common finding in ASD.</p>
<p>Male fetuses exhibit ample testosterone secretion between weeks 8 and 24 of gestational age. This testosterone production masculinizes the developing fetus’ brain. Males also produce another surge of testosterone during the perinatal period.<xref ref-type="bibr" rid="b46-cpn-15-229">46</xref>,<xref ref-type="bibr" rid="b47-cpn-15-229">47)</xref> Considering these particularities, subjects of pre-pubertal age were selected, presuming that most of the masculinizing effect on their brain would have been exerted prenatally and/or perinatally. Moreover, the prenatal testosterone is an indicator that can be estimated from the 2D:4D ratios. Thus, to minimize confounding factors linked to sex hormones, we aimed to study males aged 48 to 96 months (i.e., 4 to 8 years old). Apart from the direct influence on <italic>RALDH1</italic> expression, testosterone directly influences the functions of the MCL circuit as well.<xref ref-type="bibr" rid="b48-cpn-15-229">48)</xref> The midbrain dopaminergic system has been specifically reported to be both morphologically and functionally sexually dimorphic.<xref ref-type="bibr" rid="b8-cpn-15-229">8</xref>,<xref ref-type="bibr" rid="b49-cpn-15-229">49)</xref> As a consequence, behavioral and imaging studies revealed gender differences at the cognitive and behavioral level, specifically involving the MCL circuit.<xref ref-type="bibr" rid="b8-cpn-15-229">8</xref>,<xref ref-type="bibr" rid="b50-cpn-15-229">50)</xref> Our results regarding the 2D:4D ratios suggested that the autistic subjects and the controls were prenatally exposed to comparable levels of testosterone. Thus, our study did not confirm the hypothesis which states that ASD are associated with increased levels of prenatal testosterone.<xref ref-type="bibr" rid="b35-cpn-15-229">35)</xref> Although other studies have shown that testosterone directly influences RALDH1 expression, our data showed that there was no significant correlation between the 2D:4D ratios and the RALDH1 level.<xref ref-type="bibr" rid="b31-cpn-15-229">31)</xref> It is possible that <italic>RALDH1</italic> expression is tightly regulated by sex hormones only during the brain development, when the “transfer of signaling” from sex hormones to RA is vital.<xref ref-type="bibr" rid="b34-cpn-15-229">34)</xref></p>
<p>RALDH1 has not been investigated in autistic subjects, so far. RALDH1 has been previously proposed as a peripheral marker for Parkinson’s disease, a condition characterized by the degeneration of another dopaminergic modulatory system of the brain originating in the midbrain’s <italic>substantia nigra</italic>.<xref ref-type="bibr" rid="b6-cpn-15-229">6</xref>,<xref ref-type="bibr" rid="b51-cpn-15-229">51)</xref> More importantly, a study reported low RALDH1 levels in the VTA of schizophrenic patients.<xref ref-type="bibr" rid="b13-cpn-15-229">13)</xref> Schizophrenia, a neuropsychiatric disease with hypothesized dopaminergic involvement, is primarily treated with dopaminergic antagonists such as risperidone and aripiprazole, also used in the control of ASD-associated behavior.<xref ref-type="bibr" rid="b20-cpn-15-229">20)</xref> Even though schizophrenia and ASD are known to share behavioral traits, dopaminergic involvement in ASD remains disputed.<xref ref-type="bibr" rid="b52-cpn-15-229">52)</xref> Furthermore, although one study reported significantly elevated plasmatic 4-HNE PAs levels in autistic children,<xref ref-type="bibr" rid="b21-cpn-15-229">21)</xref> our study did not reproduce these results; by contrast, we found a slightly lower 4-HNE PAs level in autistic patients compared to controls. Likewise, we found no significant difference in GSH level between the two groups, although studies reported lower GSH levels in autistic subjects compared to controls.<xref ref-type="bibr" rid="b30-cpn-15-229">30)</xref></p>
<p>Whereas our study has reached its aims, it had several limitations. Given that we tested a new research hypothesis, our study was conducted on small samples. Thus, we avoided spending too many resources on studying a solely hypothesized association. However, our ability to make broader generalizations from the results is limited and a larger confirmatory study is needed. Second, given the conducted testosterone inferences, only males aged 48 to 96 months old were selected. Although the ASD have a strong male bias<xref ref-type="bibr" rid="b3-cpn-15-229">3)</xref> with possible sex hormones involvement, larger samples representing both genders and wider range of ages would more accurately represent the target populations. Lastly, there was a significant age difference between the autistic subjects and healthy controls. Considering that this significant age difference could have acted as a confounding factor, we further explored this possibility. Introducing the data into a linear regression model, we found a moderate correlation between age and RALDH1 level (r=0.389, <italic>p</italic>=0.031). Despite this moderate correlation, only 15.1% of the total variation of the RALDH1 levels can be explained by age (r<sub>2</sub>=0.151). The literature lacks information regarding the variation of erythrocyte RALDH1 levels across age. Thus, we further determined the level of hemoglobin in each sample and considered it as an erythrocyte reference protein for the RALDH1 level. As expected, the mean hemoglobin level in the ASD group was lower than that of the control group (99.56 mg/ml compared to 117.47 mg/ml, respectively), considering the well-known variation of hemoglobin across age.<xref ref-type="bibr" rid="b53-cpn-15-229">53)</xref> However, unlike the difference in RALDH1 level, the difference in hemoglobin level between groups was not statistically significant (<italic>p</italic>=0.066). The comparable hemoglobin levels suggest that even if age has a similar influence on RALDH1 level as it has on hemoglobin, it would not entirely explain RALDH1’s significantly lower level. Therefore, there might be another factor, besides age, that can account for the significantly lower levels of RALDH1 in autistic children.</p>
<p>One important direction that remains to be explored is the role of RALDH1 as a source of RA in the developing brain.<xref ref-type="bibr" rid="b54-cpn-15-229">54)</xref> RALDH1 is developmentally expressed in specific ventral midbrain cells corresponding to dopamine progenitors.<xref ref-type="bibr" rid="b55-cpn-15-229">55)</xref> It is likely that newborn neurons are exposed to the RALDH1-derived RA in order to acquire specific dopaminergic differentiation.<xref ref-type="bibr" rid="b56-cpn-15-229">56)</xref> Given that it is a dynamic and complex process which requires real-time observation, it is technically difficult to unravel the molecular machinery that supports the development and function of specific brain areas, such as VTA. The use of patient derived induced pluripotent stem cells (iPSC) recently provided an important opportunity to closely study the behavior of specific types of neurons in certain disorders. It would be of great interest to explore midbrain dopaminergic neurons derived from autistic patients, as this type of cells has already been differentiated from iPSC from Parkinson’s disease patients.<xref ref-type="bibr" rid="b57-cpn-15-229">57)</xref> This model would provide a better understanding of the molecular pathways involved in the development and function of the dopaminergic neurons in autistic patients.</p>
<p>We conclude that RALDH1 levels are low in a subset of autistic subjects, possibly reflecting a midbrain dopaminergic dysfunction, with long-lasting effects on high order brain functions, such as motivation, emotional behavior and cognition.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported by the Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania under Grant 1493/12/28.01.2014. The authors report no conflict of interest.</p>
</ack>
<ref-list>
<title>REFERENCES</title>
<ref id="b1-cpn-15-229">
<label>1</label>
<element-citation publication-type="book">
<collab>American Psychiatric Association</collab>
<article-title>Autism Spectrum Disorder, 299.00 (F84.0)</article-title>
<source/>Diagnostic and Statistical Manual of Mental Disorders: DSM-5
          <edition>5th ed</edition>
<publisher-loc>Arlington, VA</publisher-loc>
<publisher-name>American Psychiatric Publishing</publisher-name>
<year>2013</year>
</element-citation>
</ref>
<ref id="b2-cpn-15-229">
<label>2</label>
<element-citation publication-type="journal">
<collab>Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention</collab>
<article-title>Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008</article-title>
<source/>MMWR Surveill Summ
          <year>2012</year>
<volume>61</volume>
<issue>SS03</issue>
<fpage>1</fpage>
<lpage>19</lpage>
</element-citation>
</ref>
<ref id="b3-cpn-15-229">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakrabarti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fombonne</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Pervasive developmental disorders in preschool children</article-title>
<source/>JAMA
          <year>2001</year>
<volume>285</volume>
<fpage>3093</fpage>
<lpage>3099</lpage>
<pub-id pub-id-type="doi">10.1001/jama.285.24.3093</pub-id>
<pub-id pub-id-type="pmid">11427137</pub-id>
</element-citation>
</ref>
<ref id="b4-cpn-15-229">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Advances in autism</article-title>
<source/>Annu Rev Med
          <year>2009</year>
<volume>60</volume>
<fpage>367</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.med.60.053107.121225</pub-id>
<!--<pub-id pub-id-type="pmcid">3645857</pub-id>-->
<pub-id pub-id-type="pmid">19630577</pub-id>
</element-citation>
</ref>
<ref id="b5-cpn-15-229">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altevogt</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Hanson</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Leshner</surname>
<given-names>AI</given-names>
</name>
</person-group>
<article-title>Autism and the environment: challenges and opportunities for research</article-title>
<source/>Pediatrics
          <year>2008</year>
<volume>121</volume>
<fpage>1225</fpage>
<lpage>1229</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2007-3000</pub-id>
<pub-id pub-id-type="pmid">18519493</pub-id>
</element-citation>
</ref>
<ref id="b6-cpn-15-229">
<label>6</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Paradiso</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Chemical control of the brain and the behavior</article-title>
<person-group person-group-type="editor">
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Paradiso</surname>
<given-names>MA</given-names>
</name>
</person-group>
<source/>Neuroscience: exploring the brain
          <edition>3rd ed</edition>
<publisher-loc>Philadelphia, PA</publisher-loc>
<publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
<year>2007</year>
<fpage>481</fpage>
<lpage>509</lpage>
</element-citation>
</ref>
<ref id="b7-cpn-15-229">
<label>7</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sydor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RY</given-names>
</name>
</person-group>
<article-title>Widely projecting systems: monoamines, acetylcholine, and orexin</article-title>
<person-group person-group-type="editor">
<name>
<surname>Nestler</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>SE</given-names>
</name>
</person-group>
<source/>Molecular neuropharmacology: a foundation for clinical neuroscience
          <edition>2nd ed</edition>
<publisher-loc>New York</publisher-loc>
<publisher-name>McGraw-Hill Medical</publisher-name>
<year>2001</year>
<fpage>179</fpage>
</element-citation>
</ref>
<ref id="b8-cpn-15-229">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillies</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Virdee</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dalley</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Sex-dependent diversity in ventral tegmental dopaminergic neurons and developmental programing: A molecular, cellular and behavioral analysis</article-title>
<source/>Neuroscience
          <year>2014</year>
<volume>282</volume>
<fpage>69</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.05.033</pub-id>
<!--<pub-id pub-id-type="pmcid">4245713</pub-id>-->
<pub-id pub-id-type="pmid">24943715</pub-id>
</element-citation>
</ref>
<ref id="b9-cpn-15-229">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Holm-Waters</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tedroff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carlsson</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence</article-title>
<source/>Annu Rev Pharmacol Toxicol
          <year>2001</year>
<volume>41</volume>
<fpage>237</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.pharmtox.41.1.237</pub-id>
<pub-id pub-id-type="pmid">11264457</pub-id>
</element-citation>
</ref>
<ref id="b10-cpn-15-229">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ernst</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zametkin</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Matochik</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Pascualvaca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Low medial prefrontal dopaminergic activity in autistic children</article-title>
<source/>Lancet
          <year>1997</year>
<volume>350</volume>
<fpage>638</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)63326-0</pub-id>
<pub-id pub-id-type="pmid">9288051</pub-id>
</element-citation>
</ref>
<ref id="b11-cpn-15-229">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott-Van Zeeland</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Dapretto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ghahremani</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Poldrack</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bookheimer</surname>
<given-names>SY</given-names>
</name>
</person-group>
<article-title>Reward processing in autism</article-title>
<source/>Autism Res
          <year>2010</year>
<volume>3</volume>
<fpage>53</fpage>
<lpage>67</lpage>
<!--<pub-id pub-id-type="pmcid">3076289</pub-id>-->
<pub-id pub-id-type="pmid">20437601</pub-id>
</element-citation>
</ref>
<ref id="b12-cpn-15-229">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dichter</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Felder</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Rittenberg</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Sasson</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Bodfish</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Reward circuitry function in autism spectrum disorders</article-title>
<source/>Soc Cogn Affect Neurosci
          <year>2012</year>
<volume>7</volume>
<fpage>160</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1093/scan/nsq095</pub-id>
<!--<pub-id pub-id-type="pmcid">3277365</pub-id>-->
<pub-id pub-id-type="pmid">21148176</pub-id>
</element-citation>
</ref>
<ref id="b13-cpn-15-229">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Buervenich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carmine</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anvret</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson’s disease and in the ventral tegmental area in schizophrenia</article-title>
<source/>Neurobiol Dis
          <year>2003</year>
<volume>14</volume>
<fpage>637</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2003.09.001</pub-id>
<pub-id pub-id-type="pmid">14678778</pub-id>
</element-citation>
</ref>
<ref id="b14-cpn-15-229">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchitti</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Brocker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stagos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vasiliou</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase super-family</article-title>
<source/>Expert Opin Drug Metab Toxicol
          <year>2008</year>
<volume>4</volume>
<fpage>697</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="doi">10.1517/17425255.4.6.697</pub-id>
<!--<pub-id pub-id-type="pmcid">2658643</pub-id>-->
<pub-id pub-id-type="pmid">18611112</pub-id>
</element-citation>
</ref>
<ref id="b15-cpn-15-229">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Role of retinoid signalling in the adult brain</article-title>
<source/>Prog Neurobiol
          <year>2005</year>
<volume>75</volume>
<fpage>275</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2005.03.002</pub-id>
<pub-id pub-id-type="pmid">15882777</pub-id>
</element-citation>
</ref>
<ref id="b16-cpn-15-229">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Noorlander</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>von Oerthel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van der Linden</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Burbach</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency</article-title>
<source/>Development
          <year>2007</year>
<volume>134</volume>
<fpage>2673</fpage>
<lpage>2684</lpage>
<pub-id pub-id-type="doi">10.1242/dev.02865</pub-id>
<pub-id pub-id-type="pmid">17592014</pub-id>
</element-citation>
</ref>
<ref id="b17-cpn-15-229">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choudhary</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vergara</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nees</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Piatigorsky</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of aldehyde dehydrogenase isozymes in the defense of rat lens and human lens epithelial cells against oxidative stress</article-title>
<source/>Invest Ophthalmol Vis Sci
          <year>2005</year>
<volume>46</volume>
<fpage>259</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1167/iovs.04-0120</pub-id>
<pub-id pub-id-type="pmid">15623782</pub-id>
</element-citation>
</ref>
<ref id="b18-cpn-15-229">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchitti</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Deitrich</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Vasiliou</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase</article-title>
<source/>Pharmacol Rev
          <year>2007</year>
<volume>59</volume>
<fpage>125</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1124/pr.59.2.1</pub-id>
<pub-id pub-id-type="pmid">17379813</pub-id>
</element-citation>
</ref>
<ref id="b19-cpn-15-229">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maring</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Deitrich</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Partial purification and properties of human brain aldehyde dehydrogenases</article-title>
<source/>J Neurochem
          <year>1985</year>
<volume>45</volume>
<fpage>1903</fpage>
<lpage>1910</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.1985.tb10550.x</pub-id>
<pub-id pub-id-type="pmid">4056797</pub-id>
</element-citation>
</ref>
<ref id="b20-cpn-15-229">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Costas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Melendez-Ferro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Basal ganglia pathology in schizophrenia: dopamine connections and anomalies</article-title>
<source/>J Neurochem
          <year>2010</year>
<volume>113</volume>
<fpage>287</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06604.x</pub-id>
<!--<pub-id pub-id-type="pmcid">2929831</pub-id>-->
<pub-id pub-id-type="pmid">20089137</pub-id>
</element-citation>
</ref>
<ref id="b21-cpn-15-229">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pecorelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cerrone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Non-protein-bound iron and 4-hydroxynonenal protein adducts in classic autism</article-title>
<source/>Brain Dev
          <year>2013</year>
<volume>35</volume>
<fpage>146</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2012.03.011</pub-id>
<pub-id pub-id-type="pmid">22534237</pub-id>
</element-citation>
</ref>
<ref id="b22-cpn-15-229">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kardon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Legeza</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lizák</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mandl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Margittai</surname>
<given-names>É</given-names>
</name>
<etal></etal>
</person-group>
<article-title>On the role of 4-hydroxynonenal in health and disease</article-title>
<source/>Biochim Biophys Acta
          <year>2015</year>
<volume>1852</volume>
<fpage>826</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2015.01.015</pub-id>
<pub-id pub-id-type="pmid">25643868</pub-id>
</element-citation>
</ref>
<ref id="b23-cpn-15-229">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Marnett</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>Systems analysis of protein modification and cellular responses induced by electrophile stress</article-title>
<source/>Acc Chem Res
          <year>2010</year>
<volume>43</volume>
<fpage>673</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="doi">10.1021/ar900286y</pub-id>
<!--<pub-id pub-id-type="pmcid">2873822</pub-id>-->
<pub-id pub-id-type="pmid">20218676</pub-id>
</element-citation>
</ref>
<ref id="b24-cpn-15-229">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selley</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson’s disease</article-title>
<source/>Free Radic Biol Med
          <year>1998</year>
<volume>25</volume>
<fpage>169</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/S0891-5849(98)00021-5</pub-id>
<pub-id pub-id-type="pmid">9667492</pub-id>
</element-citation>
</ref>
<ref id="b25-cpn-15-229">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>White</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Uh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sidhu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation</article-title>
<source/>Brain Res
          <year>2003</year>
<volume>968</volume>
<fpage>102</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(02)04279-8</pub-id>
<pub-id pub-id-type="pmid">12644268</pub-id>
</element-citation>
</ref>
<ref id="b26-cpn-15-229">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siddiqui</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kashyap</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chandra</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence of cytotoxic doses of 4-hydroxynonenal on selected neurotransmitter receptors in PC-12 cells</article-title>
<source/>Toxicol In Vitro
          <year>2008</year>
<volume>22</volume>
<fpage>1681</fpage>
<lpage>1688</lpage>
<pub-id pub-id-type="doi">10.1016/j.tiv.2008.07.001</pub-id>
<pub-id pub-id-type="pmid">18672050</pub-id>
</element-citation>
</ref>
<ref id="b27-cpn-15-229">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleuranceau-Morel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Barrier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fauconneau</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Piriou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huguet</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Origin of 4-hydroxynonenal incubation-induced inhibition of dopamine transporter and Na+/K+ adenosine triphosphate in rat striatal synaptosomes</article-title>
<source/>Neurosci Lett
          <year>1999</year>
<volume>277</volume>
<fpage>91</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(99)00652-7</pub-id>
<pub-id pub-id-type="pmid">10624817</pub-id>
</element-citation>
</ref>
<ref id="b28-cpn-15-229">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strange</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Spiteri</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ramachandran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Glutathione-S-transferase family of enzymes</article-title>
<source/>Mutat Res
          <year>2001</year>
<volume>482</volume>
<fpage>21</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/S0027-5107(01)00206-8</pub-id>
<pub-id pub-id-type="pmid">11535245</pub-id>
</element-citation>
</ref>
<ref id="b29-cpn-15-229">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forman</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rinna</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Glutathione: overview of its protective roles, measurement, and biosynthesis</article-title>
<source/>Mol Aspects Med
          <year>2009</year>
<volume>30</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.mam.2008.08.006</pub-id>
<!--<pub-id pub-id-type="pmcid">2696075</pub-id>-->
<pub-id pub-id-type="pmid">18796312</pub-id>
</element-citation>
</ref>
<ref id="b30-cpn-15-229">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hormozi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Makarem</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abotorabi-Zarchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Firoozabadi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Glutathione-related factors and oxidative stress in autism, a review</article-title>
<source/>Curr Med Chem
          <year>2012</year>
<volume>19</volume>
<fpage>4000</fpage>
<lpage>4005</lpage>
<pub-id pub-id-type="doi">10.2174/092986712802002572</pub-id>
<pub-id pub-id-type="pmid">22708999</pub-id>
</element-citation>
</ref>
<ref id="b31-cpn-15-229">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rzhetsky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Human aldehyde dehydrogenase gene family</article-title>
<source/>Eur J Biochem
          <year>1998</year>
<volume>251</volume>
<fpage>549</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="doi">10.1046/j.1432-1327.1998.2510549.x</pub-id>
<pub-id pub-id-type="pmid">9490025</pub-id>
</element-citation>
</ref>
<ref id="b32-cpn-15-229">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shipley</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Loose-Mitchell</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Stancel</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Broaddus</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pickar</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Coordinate regulation of the production and signaling of retinoic acid by estrogen in the human endometrium</article-title>
<source/>J Clin Endocrinol Metab
          <year>2003</year>
<volume>88</volume>
<fpage>2157</fpage>
<lpage>2163</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2002-021844</pub-id>
<pub-id pub-id-type="pmid">12727970</pub-id>
</element-citation>
</ref>
<ref id="b33-cpn-15-229">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-Fernández</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>del Mazo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The cytosolic aldehyde dehydrogenase gene (Aldh1) is developmentally expressed in Leydig cells</article-title>
<source/>FEBS Lett
          <year>1997</year>
<volume>407</volume>
<fpage>225</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(97)00352-9</pub-id>
<pub-id pub-id-type="pmid">9166904</pub-id>
</element-citation>
</ref>
<ref id="b34-cpn-15-229">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrosino</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Disilvestro</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ziouzenkova</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Aldehyde dehydrogenase 1A1: friend or foe to female metabolism?</article-title>
<source/>Nutrients
          <year>2014</year>
<volume>6</volume>
<fpage>950</fpage>
<lpage>973</lpage>
<pub-id pub-id-type="doi">10.3390/nu6030950</pub-id>
<!--<pub-id pub-id-type="pmcid">3967171</pub-id>-->
<pub-id pub-id-type="pmid">24594504</pub-id>
</element-citation>
</ref>
<ref id="b35-cpn-15-229">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Auyeung</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nørgaard-Pedersen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hougaard</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Abdallah</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Melgaard</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated fetal steroidogenic activity in autism</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>369</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2014.48</pub-id>
<pub-id pub-id-type="pmid">24888361</pub-id>
</element-citation>
</ref>
<ref id="b36-cpn-15-229">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wheelwright</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The 2nd to 4th digit ratio and autism</article-title>
<source/>Dev Med Child Neurol
          <year>2001</year>
<volume>43</volume>
<fpage>160</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2001.tb00181.x</pub-id>
<pub-id pub-id-type="pmid">11263685</pub-id>
</element-citation>
</ref>
<ref id="b37-cpn-15-229">
<label>37</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Schopler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bourgondien</surname>
<given-names>ME</given-names>
</name>
</person-group>
<source/>The childhood autism rating scale (CARS)
          <edition>2nd ed</edition>
<publisher-loc>Los Angeles, CA</publisher-loc>
<publisher-name>Western Psychological Services</publisher-name>
<year>2010</year>
</element-citation>
</ref>
<ref id="b38-cpn-15-229">
<label>38</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
</person-group>
<source/>Autism diagnostic observation schedule: ADOS-2
          <edition>2nd ed</edition>
<publisher-loc>Los Angeles, CA</publisher-loc>
<publisher-name>Western Psychological Service</publisher-name>
<year>2012</year>
</element-citation>
</ref>
<ref id="b39-cpn-15-229">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akerboom</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Sies</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples</article-title>
<source/>Methods Enzymol
          <year>1981</year>
<volume>77</volume>
<fpage>373</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1016/S0076-6879(81)77050-2</pub-id>
<pub-id pub-id-type="pmid">7329314</pub-id>
</element-citation>
</ref>
<ref id="b40-cpn-15-229">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Bruin</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Verheij</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wiegman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ferdinand</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Differences in finger length ratio between males with autism, pervasive developmental disorder-not otherwise specified, ADHD, and anxiety disorders</article-title>
<source/>Dev Med Child Neurol
          <year>2006</year>
<volume>48</volume>
<fpage>962</fpage>
<lpage>965</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162206002118</pub-id>
<pub-id pub-id-type="pmid">17109783</pub-id>
</element-citation>
</ref>
<ref id="b41-cpn-15-229">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canitano</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Self injurious behavior in autism: clinical aspects and treatment with risperidone</article-title>
<source/>J Neural Transm (Vienna)
          <year>2006</year>
<volume>113</volume>
<fpage>425</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-005-0337-x</pub-id>
<pub-id pub-id-type="pmid">16075185</pub-id>
</element-citation>
</ref>
<ref id="b42-cpn-15-229">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sahraeizadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial</article-title>
<source/>Child Psychiatry Hum Dev
          <year>2014</year>
<volume>45</volume>
<fpage>185</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1007/s10578-013-0390-x</pub-id>
<pub-id pub-id-type="pmid">23801256</pub-id>
</element-citation>
</ref>
<ref id="b43-cpn-15-229">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nozaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Administration of secretin for autism alters dopamine metabolism in the central nervous system</article-title>
<source/>Brain Dev
          <year>2006</year>
<volume>28</volume>
<fpage>99</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2005.05.005</pub-id>
<pub-id pub-id-type="pmid">16168596</pub-id>
</element-citation>
</ref>
<ref id="b44-cpn-15-229">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emanuele</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Does reverse transport of dopamine play a role in autism?</article-title>
<source/>EBioMedicine
          <year>2015</year>
<volume>2</volume>
<fpage>98</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1016/j.ebiom.2015.01.012</pub-id>
<!--<pub-id pub-id-type="pmcid">4484826</pub-id>-->
<pub-id pub-id-type="pmid">26137546</pub-id>
</element-citation>
</ref>
<ref id="b45-cpn-15-229">
<label>45</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Chauhan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>T</given-names>
</name>
</person-group>
<source/>Autism: oxidative stress, inflammation, and immune abnormalities
          <publisher-loc>Boca Raton, FL</publisher-loc>
<publisher-name>Taylor &amp; Francis</publisher-name>
<year>2009</year>
<pub-id pub-id-type="doi">10.1201/9781420068870</pub-id>
</element-citation>
</ref>
<ref id="b46-cpn-15-229">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auyeung</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ashwin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Knickmeyer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hackett</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Fetal testosterone and autistic traits</article-title>
<source/>Br J Psychol
          <year>2009</year>
<volume>100</volume>
<fpage>1</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1348/000712608X311731</pub-id>
<pub-id pub-id-type="pmid">18547459</pub-id>
</element-citation>
</ref>
<ref id="b47-cpn-15-229">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auyeung</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Prenatal and postnatal hormone effects on the human brain and cognition</article-title>
<source/>Pflugers Arch
          <year>2013</year>
<volume>465</volume>
<fpage>557</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="doi">10.1007/s00424-013-1268-2</pub-id>
<pub-id pub-id-type="pmid">23588379</pub-id>
</element-citation>
</ref>
<ref id="b48-cpn-15-229">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kritzer</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Creutz</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>9525</fpage>
<lpage>9535</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2637-08.2008</pub-id>
<!--<pub-id pub-id-type="pmcid">2613180</pub-id>-->
<pub-id pub-id-type="pmid">18799684</pub-id>
</element-citation>
</ref>
<ref id="b49-cpn-15-229">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laakso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vilkman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haaparanta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Solin</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Syvälahti</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects</article-title>
<source/>Biol Psychiatry
          <year>2002</year>
<volume>52</volume>
<fpage>759</fpage>
<lpage>763</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(02)01369-0</pub-id>
<pub-id pub-id-type="pmid">12372667</pub-id>
</element-citation>
</ref>
<ref id="b50-cpn-15-229">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diekhof</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Keil</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Obst</surname>
<given-names>KU</given-names>
</name>
<name>
<surname>Henseler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dechent</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Falkai</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A functional neuroimaging study assessing gender differences in the neural mechanisms underlying the ability to resist impulsive desires</article-title>
<source/>Brain Res
          <year>2012</year>
<volume>1473</volume>
<fpage>63</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2012.07.010</pub-id>
<pub-id pub-id-type="pmid">22814146</pub-id>
</element-citation>
</ref>
<ref id="b51-cpn-15-229">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grünblatt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zehetmayer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jost</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Riederer</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease</article-title>
<source/>J Neural Transm (Vienna)
          <year>2010</year>
<volume>117</volume>
<fpage>1387</fpage>
<lpage>1393</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-010-0509-1</pub-id>
<pub-id pub-id-type="pmid">21069393</pub-id>
</element-citation>
</ref>
<ref id="b52-cpn-15-229">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Minshew</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Seaton</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>High-functioning autism and schizophrenia: a comparison of an early and late onset neurodevelopmental disorder</article-title>
<source/>Arch Clin Neuropsychol
          <year>2002</year>
<volume>17</volume>
<fpage>461</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1093/arclin/17.5.461</pub-id>
<pub-id pub-id-type="pmid">14592000</pub-id>
</element-citation>
</ref>
<ref id="b53-cpn-15-229">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irwin</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Kirchner</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Anemia in children</article-title>
<source/>Am Fam Physician
          <year>2001</year>
<volume>64</volume>
<fpage>1379</fpage>
<lpage>1386</lpage>
<pub-id pub-id-type="pmid">11681780</pub-id>
</element-citation>
</ref>
<ref id="b54-cpn-15-229">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCaffery</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dräger</surname>
<given-names>UC</given-names>
</name>
</person-group>
<article-title>High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1994</year>
<volume>91</volume>
<fpage>7772</fpage>
<lpage>7776</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.91.16.7772</pub-id>
<!--<pub-id pub-id-type="pmcid">44484</pub-id>-->
<pub-id pub-id-type="pmid">8052659</pub-id>
</element-citation>
</ref>
<ref id="b55-cpn-15-229">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niederreither</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fraulob</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Garnier</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Chambon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dollé</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Differential expression of retinoic acid-synthesizing (RALDH) enzymes during fetal development and organ differentiation in the mouse</article-title>
<source/>Mech Dev
          <year>2002</year>
<volume>110</volume>
<fpage>165</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1016/S0925-4773(01)00561-5</pub-id>
<pub-id pub-id-type="pmid">11744377</pub-id>
</element-citation>
</ref>
<ref id="b56-cpn-15-229">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Götz</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Radial glia: multi-purpose cells for vertebrate brain development</article-title>
<source/>Trends Neurosci
          <year>2002</year>
<volume>25</volume>
<fpage>235</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-2236(02)02156-2</pub-id>
<pub-id pub-id-type="pmid">11972958</pub-id>
</element-citation>
</ref>
<ref id="b57-cpn-15-229">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devine</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ryten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vodicka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Burdon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus</article-title>
<source/>Nat Commun
          <year>2011</year>
<volume>2</volume>
<fpage>440</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms1453</pub-id>
<pub-id pub-id-type="pmid">21863007</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-cpn-15-229" orientation="portrait" position="float">
<label>Fig. 1</label>
<caption>
<p>Comparison of erythrocyte retinal dehydrogenase 1 (RALDH1) levels (pg/ml) between the control group (n=13) and the autism spectrum disorder (ASD) group (n=18).</p>
<p>*<italic>p</italic>=0.032, significantly different from healthy controls.</p>
</caption>
<graphic xlink:href="cpn-15-229f1"></graphic>
</fig>
<fig id="f2-cpn-15-229" orientation="portrait" position="float">
<label>Fig. 2</label>
<caption>
<p>Comparison of serum 4-hydroxynonenal protein adducts (4-HNE PAs) levels (μg/ml) between the control group (n=13) and the autism spectrum disorder (ASD) group (n=18). No significant differences between groups were reported.</p>
</caption>
<graphic xlink:href="cpn-15-229f2"></graphic>
</fig>
<fig id="f3-cpn-15-229" orientation="portrait" position="float">
<label>Fig. 3</label>
<caption>
<p>Comparison of erythrocyte glutathione (GSH) levels (μg/ml) between the control group (n=13) and the autism spectrum disorder (ASD) group (n=18). No significant differences between groups were reported.</p>
</caption>
<graphic xlink:href="cpn-15-229f3"></graphic>
</fig>
<fig id="f4-cpn-15-229" orientation="portrait" position="float">
<label>Fig. 4</label>
<caption>
<p>Comparison of the second and fourth digit ratios (2D:4D ratios) between the control group (n=13) and the autism spectrum disorder (ASD) group (n=18). The left hand and right hand 2D:4D ratios are shown in the panel A and B, respectively. No significant differences between groups were reported.</p>
</caption>
<graphic xlink:href="cpn-15-229f4"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>